CGTLive’s Weekly Rewind – December 8, 2023

News
Article

Review top news and interview highlights from the week ending December 8, 2023.

CGTLive’s Weekly Rewind – December 1, 2023

CGTLive’s Weekly Rewind – December 8, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease

The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185).

2. FDA Approves Exa-cel, Vertex and CRISPR Therapeutics’ Gene Therapy, for Sickle Cell

The FDA’s decision was based on data from the CLIMB-121 and CLIMB-131 clinical trials, and the decision makes it the first CRISPR-based gene therapy to be approved in the US.

3. Sukumar Nagendran, MD, on Addressing Unmet Needs in Rett Syndrome With Gene Therapy

The president and head of R&D at Taysha Gene Therapies discussed the early clinical evaluation of TSHA-102.

4. Adaptimmune Submits Afami-Cel First Engineered TCR-T Therapy BLA for Synovial Sarcoma

The cell therapy yielded a median overall survival of around 17 months compared with a historical overall survival of less than 12 months.

5. Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Trial Doses First Patient

Benetic anticipates an announcement of interim results sometime around the midpoint of 2024.

Related Videos
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
© 2024 MJH Life Sciences

All rights reserved.